Russia Poised to Register COVID-19 Vaccine Developed by Chumakov Centre

MOSCOW (Sputnik) - Russia is poised to register its third vaccine against COVID-19, Anna Popova, the head of public health watchdog Rospotrebnadzor, said on Friday, noting that the clinical trials of a vaccine developed by the Chumakov research centre of the Russian Academy of Sciences were positive.

"I know that the Chumakov Centre should receive a registration certificate in the coming days, but the results from the centre are already very positive and speak for themselves", Popova said the Gaidar Forum.

The Russian government has so far registered Sputnik V, a vaccine against COVID-19 developed by the Gamaleya institute, and EpiVacCorona, developed by Russia's State Research Centre of Virology and Biotechnology Vector.

Chumakov research centre of Russian Academy of Sciences previously stated that it would begin Stage III clinical trial of its coronavirus vaccine in February.

Earlier, head of Rospotrebnadzor said that at least 10 more vaccines are being developed in Russia.